Our Take
A Phase III win in an orphan indication with a modest side effect profile and dual-use clearance (combination or monotherapy) is solid clinical validation, but the 118% disease-progression reduction versus natural history needs independent replication before claiming neuroprotection.
Why it matters
NPC is a rare, progressive neurodegenerative disorder with no prior approved disease-modifying therapy in Europe. This is the first regulatory approval of its kind in the EU market and expands treatment optionality for a patient population with limited alternatives.
Do this week
Regulatory Affairs: cross-check the EMA CHMP review documents against the Phase III crossover study protocol to confirm the statistical significance threshold and identify any post-hoc analyses that may affect reimbursement dossier construction.
EC grants first EU approval for NPC neurological therapy
The European Commission approved IntraBio's Aqneursa (levacetylleucine) for adults and children aged six years and above weighing at least 20kg who present with neurological symptoms of Niemann-Pick disease type C (NPC). The drug can be used in combination with miglustat or as monotherapy if miglustat is not tolerated. The decision followed a positive recommendation from the EMA's Committee for Medicinal Products for Human Use.
Aqneursa is delivered as 1g granules for oral suspension. Levacetylleucine is a modified amino acid designed to correct metabolic dysfunction and boost cellular energy in the central nervous system. The compound received orphan medicinal product designation during development and carries flatulence as its most frequently reported adverse event.
Phase III data supports efficacy claims but rely on single trial design
The approval rests on a Phase III randomised, double-blind, placebo-controlled crossover study measuring neurological symptom improvement and function over 12 weeks using the Scale for the Assessment and Rating of Ataxia. Treatment showed statistically significant improvement versus placebo. An ongoing open-label extension phase observed sustained improvements after the initial 12-week period.
IntraBio reported that observational comparison with a natural history control group showed treatment linked to an 118% reduction in annual disease progression at one year, with similar effects maintained at two years (per the 5-domain NPC Clinical Severity Scale, company-reported). This observational comparison is not a controlled trial and relies on retrospective natural history data, a common limitation in orphan disease development where large randomised comparator trials are often infeasible.
NPC is a progressive, inherited lysosomal storage disorder with no prior EU-approved disease-modifying treatment. The approval removes a critical unmet medical need in the European market and gives eligible patients a new option independent of miglustat availability or tolerability.
Evaluate the crossover design for your clinical context
The study's crossover design (within-patient comparison) is appropriate for stable, reversible conditions but raises questions about NPC's typical disease trajectory and whether 12-week windows adequately capture symptom stability or reversal. Practitioners should request the full CHMP assessment report to examine the statistical analysis plan, any post-hoc subgroup findings, and the tolerability data in pediatric patients, since the indication spans ages six to adult and dosing adjustments may differ by age and weight.
The 118% reduction figure (versus natural history) should not be confused with event-free survival or halted progression; it reflects a rate-of-change comparison and depends entirely on the accuracy and comparability of the historical control population. Independent prospective observational registries tracking NPC progression will be essential to validate the claimed neuroprotective effect in real-world use.